Form 4: Knight Therapeutics Subsidiary Acquires Significant Warrants in Synergy CHC Corp.

Knight Therapeutics Inc., through its wholly-owned subsidiary, has acquired 428,570 pre-funded common stock purchase warrants in Synergy CHC Corp., becoming a 10% owner.

Summary

• Knight Therapeutics Inc. (the "Reporting Person"), through its wholly-owned subsidiary, Knight Therapeutics International S.A. ("Knight Subsidiary"), has acquired 428,570 Pre-Funded Common Stock Purchase Warrants (the "Warrants") in Synergy CHC Corp. (SYNR).
• The transaction date for the acquisition of these warrants was June 11, 2025.
• The Warrants are exercisable at any time on or after June 11, 2025, at an exercise price of $0.00001 per share.
• A post-exercise beneficial ownership limitation of 19.90% applies to the Warrants.
• The Warrants are set to expire on June 11, 2026, but include automatic one-year extensions if not fully exercised due to the beneficial ownership limitation.
• Knight Therapeutics Inc. is listed as a Director and 10% Owner of Synergy CHC Corp. due to this acquisition.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The acquisition of warrants by a strategic investor like Knight Therapeutics suggests confidence in Synergy CHC Corp. and provides potential future capital or strategic alignment. The low exercise price is favorable for the investor. The beneficial ownership limitation is a minor constraint but does not detract significantly from the overall positive signal of the investment.

Positives

• The acquisition of pre-funded warrants by Knight Therapeutics, a significant pharmaceutical company, indicates a strategic investment and potential confidence in Synergy CHC Corp.'s future.
• The low exercise price of $0.00001 per share for the warrants suggests a highly favorable entry point for Knight Therapeutics into Synergy CHC Corp.'s common stock.
• The automatic one-year extensions on the warrant expiration provide flexibility for Knight Therapeutics to exercise the warrants over a longer period, especially if constrained by beneficial ownership limitations.

Negatives

• The beneficial ownership limitation of 19.90% post-exercise could restrict Knight Therapeutics' immediate ability to convert all warrants into common stock, potentially limiting their direct influence or full realization of their investment if they wish to exceed this threshold.

Risks

• The beneficial ownership limitation of 19.90% could restrict the full exercise of the warrants if it would cause the holder to exceed this threshold, potentially delaying or preventing full conversion.
• The value of the warrants is dependent on the future performance and stock price of Synergy CHC Corp., which carries inherent market risks.

Future Outlook

The Pre-Funded Common Stock Purchase Warrants are exercisable on or after June 11, 2025, and will expire on June 11, 2026, with provisions for automatic one-year extensions if full exercise is prevented by the beneficial ownership limitation. This indicates a long-term strategic interest in Synergy CHC Corp.

Industry Context

This filing indicates a strategic investment by Knight Therapeutics Inc., a Canadian specialty pharmaceutical company, into Synergy CHC Corp., which operates in the consumer health care sector. Such an investment could signal Knight Therapeutics' interest in expanding its portfolio or market presence within the broader health and wellness industry, potentially leveraging Synergy CHC Corp.'s consumer brands or distribution channels.

Related Party Transactions

• The 428,570 Warrants are held by Knight Therapeutics International S.A., a wholly-owned subsidiary of the Reporting Person, Knight Therapeutics Inc. This constitutes a related party transaction where the parent company is deemed to have beneficial ownership through its subsidiary.

Stakeholder Impact

• Shareholders of Synergy CHC Corp. may view this as a positive signal, indicating a strategic investment and potential future collaboration or support from a significant pharmaceutical entity.
• The exercise of warrants could lead to dilution for existing shareholders, although the pre-funded nature and beneficial ownership limit might mitigate immediate significant impact.

Next Steps

• Knight Therapeutics International S.A. may exercise the Pre-Funded Common Stock Purchase Warrants on or after June 11, 2025.
• The Warrants will expire on June 11, 2026, unless extended automatically due to beneficial ownership limitations.

Key Dates

Recommendation

Keywords

SEC Form 4, Beneficial Ownership, Warrants, Pre-Funded Warrants, Knight Therapeutics Inc., Synergy CHC Corp., SYNR, Insider Trading, Equity Securities, Investment, Pharmaceutical, Consumer Health Care